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An estimated one-third of the general population is affected by insomnia,
and this number is increasing due to more stressful working conditions and
the progressive aging of society. However, current treatment of insomnia
with hypnotics, gamma-aminobutyric acid A (GABAA) receptor modulators,
induces various side effects, including cognitive impairment, motor distur-
bance, dependence, tolerance, hangover, and rebound insomnia. Ramelteon
(Rozerem; Takeda Pharmaceutical Company Limited, Osaka, Japan) is an
orally active, highly selective melatonin MT1/MT2 receptor agonist. Unlike
the sedative hypnotics that target GABAA receptor complexes, ramelteon is a
chronohypnotic that acts on the melatonin MT1 and MT2 receptors, which are
primarily located in the suprachiasmatic nucleus, the body’s “master clock.”
As such, ramelteon possesses the ﬁrst new therapeutic mechanism of action
for a prescription insomnia medication in over three decades. Ramelteon has
demonstrated sleep-promoting effects in clinical trials, and coupled with its fa-
vorable safety proﬁle and lack of abuse potential or dependence, this chrono-
hypnotic provides an important treatment option for insomnia.
Introduction
Most adults have experienced insomnia or sleeplessness
at one time or another in their lives. An estimated one-
third of the general population is affected by insomnia,
and 10–15% have chronic insomnia [1]. Although most
of us know what insomnia is and how we feel and per-
form after one or more sleepless nights, few seek medical
advice. Many people remain unaware of the behavioral
and medical options available to treat insomnia. Insomnia
affects all age groups. The incidence increases with age,
and among older adults, insomnia affects women more
o f t e nt h a nm e n[ 2 ] .
The ﬁrst-generation drugs for insomnia were barbi-
turates such as pentobarbital and phenobarbital, which
were often used as sedative hypnotics/anxiolytics before
benzodiazepines largely came to be used for these pur-
poses. However, barbiturates have a high abuse potential,
and overdose can cause unconsciousness and even death
due to respiratory suppression [3–5].
Benzodiazepines, the second generation of hypnotics,
such as triazolam, lorazepam, and estazolam, have been
used for treatment of insomnia, because benzodiazepines
have a low potential for abuse and low danger of
lethal overdose [3,4,6]. However, these hypnotics pro-
duce several side effects including cognitive impairment,
psychomotor impairment, dependence, tolerance, hang-
over, rebound insomnia, and so on [7–10]. Then ben-
zodiazepine receptor agonists, the third generation of
hypnotics with non-benzodiazepine chemical structures,
such as zolpidem, zopiclone, and zaleplon, were devel-
oped to maintain sleep-inducing action and reduce side
effects such as amnesia and motor dysfunction [11–14].
It has been reported that there is no tolerance dur-
ing treatment and no or limited rebound insomnia af-
ter therapy discontinuation in the long-term use of za-
leplon, eszopiclone, and modiﬁed release formulation
of zolpidem [11,15,16]. However, at higher doses, non-
benzodiazepine hypnotics also cause similar side effects
as those caused by benzodiazepines, although the severity
of side effects differs among speciﬁc drugs [11–13,17,18–
20]. Benzodiazepine receptor agonists, including non-
benzodiazepines, have abuse and dependence poten-
tial. [18,21–23]. Furthermore, sleep produced by these
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agents is electrophysiologically different from that of
naturally occurring physiological sleep. Benzodiazepine
receptor agonists reduce rapid eye movement (REM)
sleep and increase stage 2 sleep [16,24–27]. Newer non-
benzodiazepine hypnotics, including zopiclone, zaleplon,
and zolpidem, also have been shown to decrease REM
sleep in the ﬁrst half of the night, although the effects
were milder than those of benzodiazepines such as triazo-
lam and temazepam [25,28,29]. Also, electroencephalo-
graphic (EEG) power spectral analyses revealed that there
is a decrease in low-frequency (0.25–10.0 Hz) activity
and increase in high-frequency activity in non-REM sleep
[24,25,30].
Since its discovery in 1958 [31], melatonin has been
shown to play a vital role in the regulation of circa-
dian rhythms, including the sleep–wake cycle [32–34].
The cyclic nature of melatonin’s production by the pineal
gland is controlled by neuronal output from the suprachi-
asmatic nucleus (SCN) of the hypothalamus. With regard
to sleep in humans, melatonin production is concurrent
with nocturnal sleep; the increase in endogenous mela-
tonin levels in the evening correlates with the onset of
self-reported evening sleepiness [35,36] and an increase
in sleep propensity [37].
The identiﬁcation and cloning of melatonin receptors
has increased our understanding of melatonin’s role in
sleep. In 1998, the nomenclature committee of the Inter-
national Union of Basic and Clinical Pharmacology clas-
siﬁed melatonin receptors as MT1,M T 2,a n dMT3.T h e
MT1 receptor (formerly ML1A or Mel1a)a n dM T 2 recep-
tor (formerly ML1B or Mel1b) were initially deﬁned as
high-afﬁnity binding sites (picomolar afﬁnity) in chick
and mammalian brains and retina [38–42]. MT1 receptor
mRNA has been detected in the SCN, and studies using
an MT1 receptor knockout mouse indicate that this recep-
tor mediates the acute inhibition of SCN ﬁring by mela-
tonin [33]. MT2 receptor mRNA has also been detected
in the SCN, and the activity at this receptor has been as-
sociated with the phase-shifting effects of melatonin on
circadian rhythms [32,43–45]. The MT3 binding site (for-
merly ML2) was initially deﬁned as a low-afﬁnity binding
site (nanomolar afﬁnity) in mammalian brains and pe-
ripheral organs [46], and it has recently been character-
ized as a melatonin-sensitive form of quinone reductase
2 [47,48]. MT3 has a proﬁle that is completely different
from that of the MT1 and MT2 receptors, and it is not
likely to be involved in the sleep–wake cycle [49].
The notion that direct administration of exogenous
melatonin could promote sleep has been dampened by
inconsistent efﬁcacy results in clinical trials [50–53]. Ac-
cording to the 2005 National Institutes of Health (NIH)
State-of-the-Science Conference Statement on Manifes-
tations and Management of Chronic Insomnia in Adults,
melatonin’s effect on sleep promotion is questionable
based on information from meta-analyses and consen-
sus statements. Because melatonin is not regulated by the
FDA, preparations vary in their melatonin content, mak-
ing comparisons across studies difﬁcult. Although mela-
tonin appears to be effective for the treatment of circadian
rhythm disorders [54–56], little consistent evidence ex-
ists for its efﬁcacy in the treatment of insomnia. The lim-
ited efﬁcacy of melatonin for insomnia may be partly at-
tributed to its short half-life [57,58]. A controlled-release
melatonin has been shown to improve initiation of sleep
and increase sleep efﬁciency and total sleep time in clin-
ical trials in elderly people with insomnia [59,60]. These
ﬁnding suggests that a high-afﬁnity MT1/MT2 receptor
agonist with a longer half-life than that of melatonin
might be a useful therapy for sleep disorders in this pop-
ulation. Recently, there has been a focus on the develop-
ment of hypnotic agents that selectively target melatonin
receptors [61–63].
Ramelteon [(5)-N-[2-(1,6,7,8-tetrahydro-2H-indeno
[5,4-b]turan-8-yl)ethyl]propionamide] is a melatonin
receptor agonist that shows high selectivity for the
MT1/MT2 receptors [64]. Figure 1 compares the chemical
structures of melatonin and ramelteon. Ramelteon has
a half-life of 0.83–1.90 h (much longer than that of
melatonin [58]) and undergoes a rapid, high ﬁrst-pass
metabolism [65,66]. In clinical trials, ramelteon has
demonstrated sleep-promoting effects, with no next-day
residual effects, rebound insomnia, or withdrawal effects,
making it the ﬁrst available nonscheduled prescription
insomnia medication [16,67–69]. This review summa-
rizes the preclinical data, clinical efﬁcacy, and safety
proﬁle of ramelteon.
Preclinical Pharmacology
Neurochemical Effects
High Afﬁnity for MT1/MT2 Receptors
In vitro studies have demonstrated that ramelteon is a
potent and highly selective MT1/MT2 receptor agonist
(Table 1) [70]. In studies of Chinese hamster ovary (CHO)
cells expressing human melatonin receptors, ramelteon
exhibited a 6-fold higher afﬁnity for the MT1 recep-
tor than that by melatonin [70]. Similarly, ramelteon
had a higher afﬁnity for the MT2 receptor than that of
melatonin. The dissociation equilibrium constant (Kd)
and maximal number of binding sites (Bmax)v a l u e so f
ramelteon were 15.0 ± 3.0 pM and 555 ± 114 fM/mg
protein, respectively, for the MT1 receptor, and 328 ±
12 pM and 133 ± 2 fM/mg protein, respectively, for
the MT2 receptor. The afﬁnities of ramelteon for the
MT1 and MT2 receptors were comparable to those of
2-iodomelatonin. N-acetyl-5-HT, a precursor of mela-
tonin with high afﬁnity for the MT3 binding site, showed
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Figure 1 Comparison of chemical structures
of melatonin and ramelteon,
(S)-N-[2-(1,6,7,8-tetrahyrdo-2H-indeno[5,4-
b]furan-8-yl)ethyl]propionamide.
Table 1 Receptor binding characteristics
Afﬁnity (Ki) for Afﬁnity (Ki) for Afﬁnity (Ki)f o r
human MT1 receptor human MT2 receptor MT3 binding site
expressed in CHO cells expressed in CHO cells in hamster brain
Ramelteon 14 ± 0.5 pM 112 ± 5 pM 2650 ± 180 nM
Melatonin 80.7 ± 2.1 pM 383 ± 5 pM 24.1 ± 0.5 nM
2-iodomelatonin 13.1 ± 0.3 pM 188 ± 4 pM 0.964 ± 0.015 nM
N-acetyl-5-HT 81,300 ± 6900 pM 3,640,000 ± 30,000 pM 15.7 ± 2.8 nM
Prazosin >2,730,000 pM >5,370,000 pM 6.16 ± 0.46 nM
Each value represents the mean and standard error [70].
very low afﬁnity for the MT1 and MT2 receptors.
Prazosin, an α1 antagonist with high afﬁnity for the MT3
binding site [71,72], showed negligible afﬁnity for the
MT1 and MT2 receptors [70].
In studies of Syrian hamster brain, the afﬁnity of
ramelteon for the MT3 binding site was extremely weak
(Ki: 2.65 μM) relative to melatonin and 2-iodomelatonin;
the values being 24.1 nM and 0.924 nM, respectively
[70]. The afﬁnity of ramelteon for the MT3 binding site
was 1/110 that of melatonin and 1/2750 that of 2-
iodomelatonin. N-acetyl-5-HT and prazosin also showed
high afﬁnities for the MT3 binding site [70], as reported
previously [38,71].
Agonistic Effect on MT1/MT2 Receptors
Melatonin receptors, when activated, inhibit adeny-
late cyclase, which leads to a decrease in cAMP
[73,74]. Ramelteon demonstrated this agonist activity
at both MT1 and MT2 receptors. In CHO cells ex-
pressing the human melatonin receptors, ramelteon
inhibited forskolin-stimulated cAMP production in a
concentration-dependent manner. [70] The half maxi-
mal inhibitory concentration (IC50) values of ramelteon
Table 2 Effects of ramelteon and other compounds on forskolin-
stimulated cAMP production in CHO cells expressing the human MT1 and
MT2 receptors
Compound Human MT1 receptor Human MT2 receptor
IC50 (pM/L) IC50 (pM/L)
Ramelteon 21.2 ± 0.5 53.4 (40.7–70.3)
Melatonin 77.8 ± 14.6 904.0 (714.0–1150.0)
2-iodomelatonin 26.8 ± 7. 5 60.7 (44.0–83.9)
MT1 receptor: each value represents the mean of 3–4 experiments with
the SEM.
MT2 receptor: each IC50 value is calculated from two experiments done
in triplicate. Figures in the parentheses indicate 95% conﬁdence intervals
of IC50 values.
and melatonin for the inhibition of cAMP production in
cells expressing MT1 receptors were 21.2 and 77.8 pM,
respectively, and in cells expressing MT2 receptors, were
53.4 and 904.0 pM, respectively (Table 2) [70]. Taken to-
gether, ramelteon’s afﬁnity and activity at MT1/MT2 re-
ceptors and its low afﬁnity for the MT3 binding site make
it a potentially more suitable sleep-promoting agent than
exogenous melatonin.
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Effects on Other Receptors and Enzymes
To help differentiate ramelteon from sedative hypnotics
that target the GABAA-receptor complex, investigators
assessed ramelteon’s afﬁnity to GABA and a wide variety
of other CNS binding sites [70]. As expected, ramelteon
did not show signiﬁcant inhibition of binding (>50%)
to 131 G-protein-coupled receptors, transporters, and
ion channels, including monoamine receptors, opioid re-
ceptors, central benzodiazepine receptors, and dopamine
transporters tested at 10 μM [70]. Moreover, ramelteon
showed no effect on enzyme activity of 54 tested en-
zymes at 10–1000 μM [70]. Melatonin caused no sig-
niﬁcant inhibition of the binding of almost all receptors,
except for 5-HT1A receptor, for which the Ki value was
5.6 μM. Ramelteon’s negligible afﬁnity to GABA, sero-
tonin, acetylcholine, glutamate, noradrenaline, opioid,
histamine, and dopamine receptors is noteworthy, as an-
cillary activity at these receptors may result in unwanted
secondary or residual effects.
Sleep-Promoting Effects
To study the sleep-promoting effects of ramelteon in cats
and monkeys using polysomnography (PSG), a cham-
ber was constructed to allow animals to move freely
while being attached to electroencephalogram (EEG) ca-
bles [49]. In freely moving cats, the effect of ramelteon
on sleep was stronger and lasted longer than the effect
of exogenous melatonin (Fig. 2) [49]. Ramelteon (0.001,
0.01, and 0.1 mg/kg, p.o.) was shown to promote sleep,
as evidenced by decreases in the percentage of time spent
awake and increases in the percentage of time spent in
slow wave sleep (SWS) and REM sleep. The median la-
tency to sleep onset (time to ﬁrst SWS lasting more than
1 min) was 24 min in cats given ramelteon 0.1 mg/kg
compared with 60 min in cats given vehicle control. In
contrast, melatonin resulted in a mild sleep-promoting
effect; melatonin (0.001–1.000 mg/kg, p.o.) showed no
statistically signiﬁcant effect on sleep latency, and the du-
ration of the sleep-promoting action of the highest dose of
melatonin (2 h) was shorter than that of ramelteon (6 h).
Ramelteon was shown to cause sleep promotion in
freely moving cats. However, it was not enough for start-
ing clinical trial, because the experimental conditions
were artiﬁcial and the effect of ramelteon was on daytime
sleep in cats. It was critical for the project to conﬁrm phar-
macological efﬁcacy in primates, focusing on the effect on
nighttime sleep, which is much more close to the clinical
use of ramelteon. Since there was no evaluation system
to assess PSG in freely moving monkeys, the authors de-
veloped the PSG assay system through a try and error
process [75]. In the study, young adult female crab-eating
macaques (Macaca fascicularis), implanted with electrodes
for EEG, electrooculogram (EOG), and electromyogram
(EMG) recording, were used, well habituated to the
recording chamber located in a soundproof, electrically
shielded room that was maintained under conditions sim-
ilar to those of the home cage under freely moving unre-
strained condition. Sleep architecure in the unrestrained
monkeys was similar to that of humans, which was also
conﬁrmed by recent reports [76].
Ramelteon (0.03 and 0.3 mg/kg, p.o.) showed sleep-
promoting effects, as evidenced by statistically signiﬁcant
increases in total duration of sleep and decreases in la-
tencies to sleep onset (time to the ﬁrst consecutive 3 min
of sleep stage) of light sleep (sleep stages 1 and 2) and
SWS (sleep stages 3 and 4) (Figs. 3–5) [75]. Melatonin
(0.3 mg/kg, p.o.) showed a statistically signiﬁcant reduc-
tion in latency to onset of light sleep but not of SWS
and had no statistically signiﬁcant effect on sleep dura-
tion [75]. The higher doses of melatonin (1 and 3 mg/kg)
had no statistically signiﬁcant effect on the latencies to
each sleep stage or sleep duration. The benzodiazepine
receptor agonist zolpidem (1–30 mg/kg, p.o.) showed no
statistically signiﬁcant effects on sleep latencies to each
sleep stage or sleep duration [75]. With regard to ob-
servable behavior, monkeys given zolpidem 30 mg/kg
displayed sedation and myorelaxation, whereas mon-
keys given either ramelteon or melatonin at any doses
showed no apparent motor dysfunction (Fig. 5) [75]. As
zolpidem showed marked sedation including myorelax-
ation at 100 mg/kg, p.o., the authors did not assess the
sleep-inducing action at this dose. They suggested that,
if they conduct the study at 100 mg/kg, it might cause
more apparent effect. Therefore, zolpidem might cause
sleep-inducing action at doses exerting marked sedation
in monkeys. A number of studies showed that zolpi-
dem causes potent reduction of sleep latency in humans
[11,14,77], suggesting that there might be a species dif-
ference in sleep induction by zolpidem. Ramelteon signif-
icantly shortened sleep latency and increased total sleep
time in monkeys. Similar clinical effects have been con-
ﬁrmed in clinical studies [69,78], suggesting that the pre-
clinical study using monkeys was valid for the prediction
of clinical efﬁcacy in humans.
Unlike the zolpidem, which increased EEG fast waves
(>14 Hz) during sleep, EEG spectra and a fast Fourier
transform (FFT) after ramelteon and melatonin admin-
istration were indistinguishable from those of naturally
occurring physiological sleep (Fig. 6) [75]. EEG power
spectral analyses in humans have shown that treatment
with benzodiazepines or zolpidem caused a signiﬁcant
reduction of low-frequency activity (0.25–10.0 Hz) and
a signiﬁcant increase in high-frequency activity in
non-REM sleep observed in healthy young subjects
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Figure 2 (A) Effects of ramelteon on sleep and wakefulness in freely
moving cats. Each value shows the mean (with standard error) percent-
age of time spent in the stages of wakefulness, SWS, or REM sleep during
each block of 2 h after drug administration. Eight of 14 cats were ran-
domlyusedineachdosegroup. ∗P≤0.05, ∗∗P≤0.01,comparedwiththe
vehicle-treated control (ANOVA). #P ≤ 0.05, ##P ≤ 0.01, compared with
the vehicle-treated control (paired t-test with Holm’s correction) [49]. (B)
Effects of melatonin on sleep and wakefulness in freely moving cats. Each
value shows the mean (with standard error) percentage of time spent in
thestagesofwakefulness,SWS,orREMsleepduringeachblockof2hafter
drug administration. Eight of 14 cats were randomly used in each dose
group. ∗P ≤ 0.05, ∗∗P ≤ 0.01, compared with the vehicle-treated control
(ANOVA). #P ≤ 0.05, ##P ≤ 0.01, compared with the vehicle-treated
control (paired t-test with Holm’s correction) [49].
[24,25,30]. Therefore, sleep induced by benzodiazepine
receptor agonists may be qualitatively different from nat-
ural sleep in terms of EEG ﬁndings. EEG spectral analyses
showed that sleep induced by ramelteon and melatonin
was indistinguishable from that of vehicle-treated control
[75], implying that MT1/MT2 receptor agonists may pro-
mote physiological sleep in animals.
Circadian Reentrainment
To assess the ability of ramelteon to shift the circadian
rhythm, a study of running-wheel activity in rats was
conducted [79]. After an abrupt 8-h advance of the light–
dark cycle, the circadian rhythm of running-wheel ac-
tivity of rats was gradually resynchronized to the new
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Figure 2 Continued.
light–dark cycle. Rats treated with ramelteon (0.1 and
1.0 mg/kg, p.o.) took less time to resynchronize to the
new light–dark cycle compared with rats that received
vehicle control (Fig. 7). Melatonin 10 mg/kg, p.o.,
also accelerated reentrainment of running-wheel activity
rhythm following the phase advance [79]. These results
indicate that ramelteon was closely mimicking the cen-
tral actions of melatonin as a circadian rhythm signal, not
simply acting as a hypnotic.
The MT2 receptor had been shown to be important for
the phase-shifting effects of melatonin in the SCN [32,43–
45]. Ramelteon induced phase advance by application at
zeitgeber time (ZT) 10 but not at ZT 6 in SCN slice in
rats. The phase-advancing effect was inhibited by an MT2
receptor antagonist, 4-phenyl-2-acetamidotetraline [80],
suggesting that MT2 receptor might be involved in the
phase-advancing effect of ramelteon.
Learning and Memory and Motor Function
On the Morris water-maze task for spatial learning and
memory, rats treated with ramelteon (3–30 mg/kg, p.o.)
and melatonin (10–100 mg/kg, p.o.) showed no statisti-
cally signiﬁcant differences from vehicle control in time
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Figure 3 Effects of ramelteon on latency to sleep onset in freely moving
monkeys. Each value shows the mean latency ± SE to each light sleep
(LS) and SWS at doses of 0.003 (A), 0.03 (B), and 0.3 mg/kg, p.o. (C). Six
monkeyswereusedineachgroup. ∗P≤ 0.05, ∗∗P≤ 0.01,comparedwith
vehicle-treated controls [paired t test with Holm correction, 103].
to ﬁnd the submerged platform (Fig. 8) or the number of
crossings of the area where the platform had been located
during training [79]. In contrast, diazepam (3–30 mg/kg,
p.o.) and triazolam (0.1–1 mg/kg p.o.) resulted in statis-
tically signiﬁcant delays in platform reaching times and
reductions in the number of platform crossings, indicat-
ing an adverse effect on learning and memory function
[79].
Figure 4 Effects of melatonin on latency to sleep onset in freely moving
monkeys. Each value shows the mean latency ± SE to light sleep (LS) and
SWS at doses of 0.3 (A), 1 (B), and 3 mg/kg (C). Six or seven monkeys were
usedineachgroup. ∗∗P≤ 0.01comparedwiththecontroltreatedvehicle
[paired t test with Holm correction, 103].
On the delayed matching to position task for memory
and attention, rats treated with ramelteon (3–30 mg/kg,
p.o.) and melatonin (10–100 mg/kg, p.o.) showed no
impairment on task performance [79]. In contrast, high
doses of diazepam (30 mg/kg, p.o.) and triazolam (1 and
3 mg/kg, p.o.) resulted in statistically signiﬁcant reduc-
tions in the number of correct responses across delays
[79].
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Figure 5 Effects of zolpidem on latency to sleep onset in freely moving
monkeys. Each value shows the mean latency ± standard error to light
sleep (LS) and SWS at doses of 1 (A), 3 (B), and 10 or 30 mg/kg, p.o.
(C). Four monkeys were used in each group.
On the rota-rod test for motor coordination, mice
treated with ramelteon, melatonin, or N-acetyl-5-HT
(3–30 mg/kg p.o.) showed no impairment on rota-rod
performance [81]. In contrast, the benzodiazepine di-
azepam (3–10 mg/kg, p.o.) induced dose-dependent im-
pairment of rota-rod performance; all of the mice in the
diazepam group 10 mg/kg failed the test (Fig. 9) [81].
Melatonin and N-acetyl-5-HT exacerbated the diazepam-
induced impairment of performance, whereas ramelteon
did not affect the diazepam-induced motor dysfunction
(Fig. 10).
Rewarding Properties, Abuse Potential,
and Dependence
On the conditioned place-preference test for rewarding
property, rats treated with ramelteon (3–30 mg/kg, p.o.)
or melatonin (10–100 mg/kg, p.o.) showed no preference
in the drug-associated compartment, indicating a low po-
tential for reinforcing behavior (Fig. 11) [79]. In contrast,
morphine (1 mg/kg, s.c.), triazolam (0.5 mg/kg, p.o.), and
diazepam (5 mg/kg, p.o.) resulted in statistically signif-
icant increases in the time spent in the drug-associated
compartment [79], consistent with reports of the reward-
ing properties that may occur with the use of benzodi-
azepines [22,82].
On a task to determine if ramelteon produces ben-
zodiazepine receptor agonist-like discriminative stimu-
lus effects, the monkeys were trained to reliably dis-
criminate between subcutaneous injections of vehicle
and the benzodiazepine midazolam using a standard 2-
lever procedure for shock avoidance [83]. Ramelteon was
then administered intravenously in lieu of midazolam
at doses of 0.32, 1.0, 3.2, 5.6, and 10.0 mg/kg. After
receiving ramelteon, the monkeys responded primarily
on the vehicle-associated lever versus the midazolam-
associated lever, indicating that these animals did not
generalize ramelteon to midazolam. In a similar study,
monkeys dependent on diazepam were trained to re-
liably discriminate between subcutaneous injections of
vehicle and ﬂumazenil (benzodiazepine antagonist) us-
ing a standard 2-lever procedure for food presentation
[83]. Ramelteon was then administered intravenously
at doses of 3.2, 5.6, and 10.0 mg/kg 15 min prior to
increasing doses of ﬂumazenil. The percentage of re-
sponses on the ﬂumazenil-associated lever was similar
between ramelteon 10 mg/kg and vehicle control, in-
dicating that ramelteon did not attenuate the effect of
ﬂumazenil.
On an operant task to assess a reinforcing effect,
rhesus monkeys were free to self-administer intra-
venous ramelteon [84]. In the 2-h testing periods, there
were no signiﬁcant differences in the number of self-
administrations (ﬁxed ratio of 50) of ramelteon at doses
ranging from 0.025–0.400 mg/kg per infusion relative to
vehicle control [84]. In contrast, pentobarbital at doses of
0.5 and 1.0 mg/kg per infusion resulted in statistically sig-
niﬁcant increases in the number of self-administrations.
When the monkeys were free to self-administer drug
(ﬁxed ratio of 5) around the clock, the mean num-
bers of self-administrations of ramelteon were compara-
ble to those of vehicle, further indicating that ramelteon
showed no positive reinforcing effect. With regard to
observable behavior, no gross behavioral changes were
noted in monkeys treated with ramelteon or vehicle
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Figure 6 Typical electroencephalographic
(EEG) spectra and fast Fourier transform (FFT)
analysis in freely moving monkey when treated
with ramelteon (0.3 mg/kg, p.o.), melatonin
(1 mg/kg, p.o.), and zolpidem (30 mg/kg, p.o.).
Typical samples were selected during non-REM
sleep. EEG, electro-oculogram (EOG) and
electromyographic (EMG) activities were
recorded [103].
Figure 7 Effects of ramelteon on
reentrainment of running-wheel activity rhythm
following an 8-hour phase advance.
Running-wheel activity in the subjective night
as a percentage of total activity in 24 hours is
shown with standard error. Ramelteon or
vehicle was administered 5–30 min before
lights out of the new light-dark cycle for 14 days
starting the day of the phase-shift. Arrows and
black bars show the phase-shift and the vehicle
or ramelteon treatment periods [36].
control. In monkeys treated with pentobarbital, hypore-
activity, slowed motion, and/or ataxia was noted.
In a long-term study to assess physical dependence
liability, monkeys received ramelteon (10 mg/kg, i.g.
catheter) daily for 1 year [83]. During weeks 14, 27,
and 40, the treatment was temporally discontinued for
5 days to assess the effects of treatment discontinuation
on operant behavior (conditioned lever pressing to ob-
tain food and avoid shock) and observable clinical signs
(such as yawning and grooming) using a paradigm sensi-
tive to benzodiazepine dependence. Daily treatment with
ramelteon had no overall effect on monkey’s behavior to
obtain food or avoid shock. Operant response rates in in-
dividual monkeys did not systematically change over the
course of the study. In addition, there were no apparent
changes in body weight, motor activity, posture, or be-
havior observed during the periods of treatment or after
discontinuation of treatment.
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Figure 8 Effects of ramelteon, melatonin, diazepam, and triazolam on the Morris water maze task in rats. Each value shows the mean time to ﬁnd the
p l a t f o r ms u b m e r g e di nt h ew a t e r( A ,B ,C ,D ) .∗P ≤ 0.025, compared with the respective vehicle control group [one-tailed Williams test, 36].
Figure 9 Percentage of mice failing the rota-rod performance test after administration of ramelteon (A), melatonin (B), N-acetyl-5-HT (C), or diazepam
(D) at the indicated doses. Twelve mice were used in each group. ∗∗P ≤ 0.01, compared with the control group treated with vehicle (chi-square test with
Holm’s correction) [81].
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Figure 10 Percentage of mice failing the rota-rod performance test af-
ter administration of diazepam alone or diazepam in combination with
ramelteon (A), melatonin (B), N-acetyl-5-HT (C) at the indicated doses.
Twelve mice were used in each group. ∗P ≤ 0.05 ∗∗P ≤ 0.01, compared
with the control group treated with vehicle (chi-square test with Holm’s
correction) [53].
Clinical Efﬁcacy and Safety
Metabolism
Rameleteon is metabolized primarily via oxidation to
hydroxyl and carbonyl derivatives, with secondary
metabolism producing glucuronide conjugates [65].
Ring-opening biotransformation results in the formation
of M-I, and hydroxylation of the carboxy-metabolite,
M-III, results in the formation of M-IV (Fig. 12) [65].
The major metabolite of ramelteon in serum is the
monohydroxylated metabolite, M-II. Cytochrome P450
(CYP)1A2 is the major isozyme involved in the hep-
atic metabolism of ramelteon; the CYP2C subfamily and
CYP3A4 isozymes are also involved to a minor de-
gree. The major metabolite in serum was M-II, hav-
ing exposure approximately 39-fold greater than that of
ramelteon at the 16-mg dose. The half-life of ramelteon
ranges from 0.83 to 1.90 h, depending on the dose [65],
Figure 11 Effect of ramelteon on place preference in rats. Increase in
time spent in the compound-associated compartment in the conditioned
place-preferencetestsinratsintheexperiment1(AandC)andexperiment
2(B).Thenumbersofratsusedareshowninparentheses.Vehiclegroups
in panels A and B are identical. ∗P ≤ 0.05, compared with the value at the
preconditioning phase (paired t-test) [79].
which is considerably longer than that of melatonin. This
might be regarded as a decisive advantage for the use
of ramelteon as a sleep promoter, because the relatively
poor efﬁciency of melatonin is presumed to be partly due
to its short half-life [57,58].
M-II is a major metabolite and is physiologically ac-
tive, and its afﬁnity for chick Mel1a/Mel1c receptors is
0.675 nM, one-ﬁfth to one-tenth the binding afﬁnity of
ramelteon, for the human MT1 and MT2 receptors, and
it is 17- to 25-fold less potent than ramelteon in in vitro
functional assays [70]. M-II also showed a potent sleep-
promoting action in freely moving cats [49]. M-II had no
signiﬁcant afﬁnities for other receptors or various enzyme
activities, as those of ramelteon, suggesting that M-II is
also an MT1/MT2 receptor selective agonist [70]. How-
ever, the levels of other metabolites are low, and also
the afﬁnities for Mel1a/Mel1c receptors are negligible, as
demonstrated by Ki values of 36.0 nM for M-III and
>236 nM for both M-I and M-IV. Thus, M-II may con-
tribute to pharmacological effects of ramelteon.
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Figure 12 Metabolic pathway of ramelteon in
humans. Ramelteon is extensively metabolized,
primarily by carboxylation and stereoselective
hydroxylation. The major metabolite of
ramelteon in serum is the monohydroxylated
metabolite, M-II.
Sleep-Promoting Effects
In randomized, double-blind, placebo-controlled clinical
trials, the sleep-promoting effects of the short- and long-
term use of ramelteon have been demonstrated in pa-
tients with chronic insomnia as well as in healthy sub-
jects subjected to a ﬁrst-night-effect model of transient
insomnia. Overnight monitoring with PSG (EEG, EOG,
and EMG) was used to objectively evaluate the ability of
ramelteon to reduce latency to persistent sleep, maintain
sleep, and increase the duration of sleep. Patients’ subjec-
tive assessments of sleep were also evaluated with a post-
sleep questionnaire. Latency to persistent sleep (deﬁned
as time in minutes to the ﬁrst of 20 consecutive epochs of
sleep on PSG) [78,85] or patient-reported sleep latency
was the primary measures in these trials.
Transient Insomnia
Ramelteon’s ability to improve transient insomnia was
assessed in two clinical trials that utilized a ﬁrst-night-
effect model of transient insomnia. In Roth et al.’s trial
of 375 healthy subjects unfamiliar with a sleep labora-
tory environment (i.e., experiencing transient insomnia),
ramelteon at doses of 16 mg and 64 mg produced statis-
tically signiﬁcant decreases in latency to persistant sleep
and increases in total sleep time, as measured with PSG
[85]. The mean latency to persistent sleep was 14.1 and
15.5 min in the ramelteon 16-mg and 64-mg groups, re-
spectively, compared with 24.6 min in the placebo group
(P ≤ 0.001 for both groups vs. placebo). The mean total
sleep times were 425.4 and 422.4 min in the 16-mg and
64-mg groups, respectively, compared with 411.3 min in
the placebo group (P ≤ 0.05 for both doses vs. placebo).
According to a post-sleep questionnaire, subjects in the
16-mg group reported statistically signiﬁcant improve-
ments in subjective sleep latency (P = 0.013; no P-value
reported for subtotal sleep time). Ramelteon was not
associated with next-day residual psychomotor impair-
ment, as measured by the Digit Symbol Substitution Test
(DSST). However, the use of the ramelteon 64-mg dose
was associated with small but statistically signiﬁcant re-
ductions in subjective next-day levels of alertness and
ability to concentrate relative to placebo. Zammit et al.
conducted a similar trial of 289 healthy subjects that
showed that latency to persistent sleep, as measured with
PSG, was 12.2 min in the ramelteon 8-mg group and
14.8 min in the ramelteon 16-mg group compared with
19.7 min in the placebo group; the 8-mg dose reached
statistical signiﬁcance (P = 0.004) [68]. The mean total
sleep time was 436.8 min and 433.1 min in the 8-mg and
16-mg groups, respectively, compared with 419.7 min in
the placebo group (P ≤ 0.05 for both groups vs. placebo).
Subjective measures of sleep latency and total sleep time
were improved, but the differences from placebo were
not statistically signiﬁcant. In this trial, ramelteon had
no signiﬁcant effects on the DSST and subjective levels
of alertness and ability to concentrate as well as on other
next-day residual effect measures including memory re-
call tests and visual analog scales (VAS) for mood and
feeling.
Chronic Insomnia
Patients with a history of chronic insomnia (primary in-
somnia as deﬁned by Diagnostic and Statistical Manual
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Figure 13 Effects of ramelteon on sleep latency in patients with chronic
insomnia under placebo-controlled, double-blind, randomized, 5-period
crossover study. All data are shown as the least square means. ∗∗∗P ≤
0.001, compared with placebo [78].
of Mental Disorders (DSM)-IV-TR for at least 3 months)
were also evaluated in clinical trials. Figure 13 illus-
trates the differences from placebo in latency to persis-
tent sleep by dose of ramelteon in these trials. In Erman
et al.’s multiple-dose cross-over study of 107 adults with
chronic insomnia, a 2-night administration of ramelteon
resulted in statistically signiﬁcant reductions in latency
to persistent sleep (P ≤ 0.001) and increases in total
sleep time (P ≤ 0.05), as measured with PSG, at each
dose tested (4–32 mg) [78]. Interestingly, all doses of
ramelteon produced similar reductions in latency to per-
sistant sleep (13.4–14.8 min more than placebo), with no
apparent dose-dependent effects, and this wide therapeu-
tic window was seen across studies. Patients who received
ramelteon 16 mg reported signiﬁcant reductions in sub-
jective sleep latency (P ≤ 0.05); no other statistically sig-
Figure 14 Latency to persistent sleep and
total sleep time, as measured by PSG, with
ramelteon 8 mg, ramelteon 16 mg, and placebo
a tw e e k s1 ,3 ,a n d5( A and B). Subjective sleep
latency and total sleep time, as measured by
the post-sleep questionnaire (C and D). For
comparisons between ramelteon dose and
placebo, ∗P ≤ 0.05, ∗∗P ≤ 0.01, and ∗∗∗P ≤
0.001 [68].
niﬁcant effects in subjective sleep ratings were observed.
Ramelteon had no statistically signiﬁcant effect on next-
day residual effect measures including the DSST, memory
recall tests, and patient-reported levels of alertness and
ability to concentrate. However, ramelteon had no sig-
niﬁcant effect on the mean wake time after sleep onset
(WASO).
In Zammit et al.’s extended trial in 405 patients with
chronic insomnia, ramelteon 8 mg and 16 mg resulted
in improvements in latency to persistent sleep and to-
tal sleep time over 5 weeks of nightly treatment, as
measured objectively by PSG and subjectively by the
post-sleep questionnaire (Fig. 14) [69]. Ramelteon had
no signiﬁcant effects on WASO. Ramelteon showed no
statistically signiﬁcant effect on the next-day DSST per-
formance. Patients in the 8-mg ramelteon group demon-
strated a small, but statistically signiﬁcant, decrease in
the mean score compared with placebo on the immedi-
ate memory recall test at week 3 and the delayed mem-
ory recall test at week 1. At other time points, no sig-
niﬁcant differences between ramelteon and placebo were
found on memory function tests. Subjective levels of
alertness and ability to concentrate were similar between
the ramelteon groups and placebo with two exceptions:
patients in the ramelteon 8-mg group reported statisti-
cally signiﬁcant improvements in the ability to concen-
trate at week 1 and the level of alertness at week 5.
This trial also included a 2-day placebo runout period
that showed that the discontinuation of ramelteon treat-
ment was not associated with either rebound insomnia
or withdrawal effects, as assessed with the Tyer Benzo-
diazepine Withdrawal Symptom Questionnaire (BWSQ).
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The BWSQ is a questionnaire that solicits speciﬁc infor-
mation on 20 symptoms commonly experienced during
withdrawal from benzodiazepine receptor agonists.
In Roth et al.’s trial of ramelteon in 100 elderly patients
(≥65 years) with chronic insomnia, a 2-night administra-
tion of either ramelteon 4 mg or ramelteon 8 mg pro-
duced statistically signiﬁcant reductions in latency to per-
sistent sleep and increases in total sleep time, as measured
with PSG [86]. The mean latency to persistent sleep was
28.7 min and 30.8 min in the 4-mg and 8-mg groups, re-
spectively, compared with 38.4 min in the placebo group
(P ≤ 0.01 for both groups vs. placebo). The mean total
sleep time was 359.4 min and 362.0 min in the 4-mg and
8-mg groups, respectively, compared with 350.4 min in
the placebo group (P ≤ 0.05 for both groups vs. placebo).
According to the post-sleep questionnaire, patients who
received ramelteon 4 mg reported statistically signiﬁcant
reductions in subjective sleep latency (P ≤ 0.05). There
were no next-day residual effects with either dose of
ramelteon, as measured with the DSST, memory recall
tests, and patient-reported levels of alertness or ability to
concentrate.
A large 5-week outpatient trial in 829 older adult pa-
tients (≥65 years) with chronic insomnia was conducted
to speciﬁcally assess subjective ratings of sleep [87]. In
this trial, nightly administration of either ramelteon
4 mg or ramelteon 8 mg produced reductions in patient-
reported sleep latency and increases in patient-reported
total sleep time at week 1, and these improvements were
sustained throughout the study. At week 1, subjective
sleep latency was 70.2 min in the 4-mg group and
70.2 min in the 8-mg group compared with 78.5 min in
the placebo group (P ≤ 0.01 for both doses vs. placebo).
At week 1, subjective total sleep time was 324.6 min
in the 4-mg group and 321.1 min in the 8-mg group
compared with 313.9 min in the placebo group (P ≤ 0.01
for 4 mg vs. placebo, P = 0.055 for 8 mg vs. placebo).
Ramelteon did not show either rebound insomnia or
withdrawal effects, according to subjective sleep latency
and BWSQ results during the 7-day placebo runout
period.
In the longest trial of ramelteon to date, 1213 pa-
tients with chronic insomnia took open-label ramelteon
(8 mg or 16 mg) nightly for 1 year [88]). Patient-reported
sleep was improved by the ﬁrst week of treatment and
was sustained throughout the remainder of the study.
Improvements in sleep latency from baseline at month
1 were 34.0% and 35.1% with the 8-mg and 16-mg
dose, respectively, and continued to improve through
month 6 (44.7% and 49.1%) and month 12 (50.3% and
52.1%). Improvements from baseline in patient-reported
total sleep time at month 1 (15.2% and 16.9%), month 6
(21.6% and 22.7%), and month 12 (25.5% and 23.9%)
were also reported with ramelteon 8-mg and 16-mg
doses, respectively. There was no evidence of rebound in-
somnia with ramelteon during the 3-day placebo runout
period.
Considering the clinical data thus far, ramelteon has
consistently demonstrated signiﬁcant sleep-promoting ef-
fects, as evidenced by reductions in sleep latency and in-
creases in sleep duration, among patients with chronic
insomnia and subjects with transient insomnia, during
both short-term and long-term treatment, in both the
sleep laboratory and outpatient setting by both objective
PSG and subjective reports. The efﬁcacy by subjective re-
ports [87] was weaker than that by objective PSG mea-
surement [69,78]. The efﬁcacy was less than that of seda-
tive hypnotics [11,15,2008]. However, the subjective ef-
ﬁcacy of ramelteon was more prominent in subjective re-
ports to questionnaire done the next morning in the sleep
laboratory than that in subjective reports done at home,
possibly suggesting that compliance is more important
for subjective evaluation of melatonin receptor agonists.
In 2005, ramelteon was approved in the United States
for the treatment of insomnia characterized by a difﬁ-
culty in sleep onset. Current data suggest that ramelteon
has no signiﬁcant effects on WASO, and the efﬁcacy for
sleep maintenance insomnia has not been conﬁrmed.
Further studies are required to clarify the effect on WASO
and search for a possible medication for sleep mainte-
nance insomnia, taking into consideration the dosage of
ramelteon and appropriate patient population.
Safety
Ramelteon was generally well tolerated across the clin-
ical trials. Most adverse events were considered mild or
moderate in severity, and very low incidences of adverse
events during ramelteon administration were observed.
Only three events were noted to occur at an incidence of
≥2% with ramelteon 8 mg (the recommended therapeu-
tic dose) vs. placebo: somnolence (5% vs. 3%), dizziness
(5% vs. 3%), and fatigue (4% vs. 2%).
In the 1-year trial of ramelteon in 1213 adults with
chronic insomnia, the overall incidence of adverse events
was similar at 6 months and 1 year [89]. The ad-
verse events were predominantly mild or moderate. At
1 year, the adverse events most frequently reported
with ramelteon 8 mg and 16 mg, respectively, were na-
sopharyngitis (10.5% and 14.9%), somnolence (9.5%
and 8.1%), upper respiratory tract infection (7.6% and
11.1%), headache (1.9% and 13.5%), and sinusitis
(1.9% and 7.8%). Of 38 subjects (3.1%) reporting a seri-
ous adverse event, only three adverse events were possi-
bly treatment related. There were no clinically meaning-
ful changes in vital signs, physical examinations, clinical
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Figure 15 Effectsoframelteononpatient-reportedsleeplatencyinolder
adults with chronic insomnia. Patients include older adults (≥65 years;
n = 829) with chronic insomnia. Placebo, ramelteon 4 mg, or ramelteon
8mgwastakennightlyfor5weeks,andpatient-reportedsleepdatawere
the collected sleep diaries. ∗P ≤ 0.05, ∗∗P ≤ 0.01, compared with the
placebo control [87].
chemistry, hematology, or urinalysis values and no elec-
trocardiogram trends to suggest adverse effects on cardiac
function over the 1 year of ramelteon treatment. No no-
table changes in endocrine and sexual/reproductive func-
tion were observed except for the mean free and total
testosterone level, which had a slight decrease in older
men that returned to normal by the ﬁnal visit of the trial.
Abuse Liability
Benzodiazepine receptor agonists, which are the most
commonly used prescription medications for treatment
of insomnia, have been associated with a potential for
abuse [18,21–23]. All benzodiazepine receptor agonists
(including the newer agents zolpidem, zaleplon, and es-
zopiclone) are classiﬁed as schedule IV controlled sub-
stances, meaning they possess some potential for abuse
and the adverse consequences of abuse (e.g., withdrawal,
psychomotor impairment, and overdose).
In a study of 14 subjects with a history of sedative hyp-
notic or anxiety drug abuse, ramelteon doses up to 160
mg (20 times the therapeutic dose) had no effect on a
wide variety of instruments including subject ratings of
mood and behavior, observer rating of mood and be-
havior, and assessments of behavioral and cognitive per-
formance [67]. Figure 15 shows that ramelteon showed
no statistically signiﬁcant effect at any time point (0.5–
24 h post dose) on representative abuse measures in-
cluding “liking” scales, the DSST, and circular lights task.
Ramelteon had no statistically signiﬁcant effect on other
questionnaire items “drug strength,” “good effects,” and
“monetary street value.” Similarly, ramelteon had no sta-
tistically signiﬁcant effect on word recall/recognition task,
enter and recall task, and balance task performance at
any dose compared with placebo. In contrast, triazolam
consistently produced a dose-related effect on all these
subjective and behavioral measures, consistent with its
proﬁle as a sedative drug with known abuse potential.
This trial demonstrates that ramelteon does not share the
pharmacologic side effect proﬁle observed among benzo-
diazepine receptor agonists.
Future Perspective
Ramelteon has been shown to improve sleep disorders
in patients suffering from transient and chronic insomnia
without causing signiﬁcant adverse events. However, it
has been suggested that melatonin receptor agonists have
opportunities to cure various diseases, including circadian
rhythm sleep disorders (CRSD), depression, Alzheimer
disease, bipolar disorder, cancer, hypertension, urinary
incontinence, and so on.
Patients with CRSD often experience sleep disruption,
daytime fatigue, and impaired mental and physical func-
tion. The prevalence of CRSD is unknown, but it has been
estimated that 5–10% of patients referred to sleep disor-
der clinics have a CRSD [90]. Among blind individuals,
non-24-h sleep-wake syndrome may occur in as many as
50% [91]. Transient CRSD, such as jet lag and shift-work
syndrome, may be quite common in the general popu-
lation. As a pharmacologic therapy for CRSD, melatonin
has shown some effectiveness [92–94], and a systematic
review of 10 trials concluded that melatonin treatment
(0.5–5.0 mg per day for 2–5 days) is effective for alleviat-
ing the symptoms of jet lag after travel across several time
zones [95].
A number of studies have shown altered melatonin
levels in depressed patients and suggested that mood dis-
orders may be related to low melatonin levels, although
the reports were not consistent [96,97]. Recently, agome-
latin, a melatonin agonist, showed some efﬁcacy in the
treatment of major depressive disorder [98,99]. Agome-
latine has been reported to have afﬁnity for 5-HT2c re-
ceptors; however, the afﬁnity was much less than that
for melatonin MT1/MT2 receptor, suggesting that antide-
pressive effect of agomelatine might be related to the ef-
fects via activation of MT1/MT2 receptors. Furthermore,
reduced melatonin levels and altered timing of melatonin
secretion were observed in patients with bipolar affective
disorder [100,101].
The secretion of endogenous melatonin declines with
aging [102], and this may be related to the sleep–
wake rhythm disturbance in elderly people [103,104].
Abnormal decreases in nocturnal melatonin have also
been observed in patients with Alzheimer disease, an-
other population prone to sleep disturbances [103–105].
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Table 3 Classiﬁcation of therapeutic drugs for insomnia
Classiﬁcation Drug Adverse events Sleep pattern
Bariturates Pentobarbital, phenobarbital Respiratory suppression, am-
nesia, loss of motor dysfunc-
tion, drug abuse, dependence
Sedative sleep
Benzodiazepme receptor ago-
nists (benzodiazepines)
Triazolam, temazepam Amnesia, loss of motor coor-
dination, drug abuse, depen-
dence
Sedative sleep
Benzodiazepme receptor ago-
nists (non-benzopdiazepines)
Zolpidem, zaleplon, zopiclone Amnesia, loss of motor coor-
dination, drug abuse, depen-
dence
Sedative sleep
MT1/MT2 receptor agonist Ramelteon No serious adverse event Physiological sleep
Administration of melatonin to Alzheimer disease pa-
tients has been found to improve signiﬁcantly sleep and
circadian abnormality [106–108]. These ﬁndings suggest
that melatonin may play a role in signiﬁcant regulation
of various physiological functions. Thus, further studies
using ramelteon, a potent and selective MT1/MT2 recep-
tor agonist well tolerated in humans, to examine its clin-
ical efﬁcacy in these disorders would be interesting and
may provide an insight into treatment options for these
patients.
Conclusion
Ramelteon shows selective afﬁnity for MT1 and MT2 re-
ceptors and acts as a full agonist. Currently, MT1 and
MT2 receptors have been suggested to be related to sleep
promotion and circadian clock such as phase advance.
Ramelteon exerts potent sleep promotion in experimen-
tal animals including cats and monkeys, without causing
any signiﬁcant adverse effects such as learning and mem-
ory impairment, impairment of motor coordination, and
drug abuse ability. The sleep induced by ramelteon can-
not be distinguished from natural sleep using FFT analysis
in monkeys, in contrast to the altered sleep pattern pro-
duced by current sedative hypnotics.
In clinical trials, ramelteon decreases sleep latency and
increases total sleep time, without causing hangover, ad-
diction, and withdrawal effects. It has no signiﬁcant ef-
fects on psychomotor and cognitive function and does not
show drug abuse potential. Taken together, the proven
clinical efﬁcacy of ramelteon combined with its safety
proﬁle positions it as a fourth-generation insomnia treat-
ment worth considering for select patients suffering from
insomnia (Table 3). Further development of ramelteon
for various diseases or disorders is expected.
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